Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897594 · ClinicalTrials.gov registry record · Phase 1
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
A Phase 1 study, sponsored by Terns.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04897594 is a Phase 1 study that has completed, run by Terns. The registered enrollment target is 52 participants.
The verdict
NCT04897594, a Phase 1 study, has completed, sponsored by Terns.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
Interventions
- OTHER Placebo
- DRUG TERN-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04897594
The ClinicalTrials.gov registry entry for NCT04897594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terns, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04897594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04897594 about?
NCT04897594 is a clinical study titled "AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis". This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
What is the current status of trial NCT04897594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2021-05-20. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT04897594?
The interventions under investigation include: Placebo (OTHER), TERN-201 (DRUG).
Who is sponsoring clinical trial NCT04897594?
This trial is sponsored by Terns, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.